Recommendation for optimal management of severe refractory asthma

Journal of Asthma and Allergy

Volumn 3, Issue , 2010, Pages 43-56

  Morjaria, Jaymin B ^a   Polosa, Riccardo ^b  

^a UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

^b UNIVERSITY OF CATANIA   (Italy)

Author keywords

Anti TNF drugs; Bronchial thermoplasty; Corticosteroids; Daclizumab; Immunological modifiers; Mepolizumab; Omalizumab; Severe asthma; Steroid sparing

Indexed keywords

EID: 84993706094     PISSN: None     EISSN: 11786965     Source Type: Journal    
DOI: 10.2147/JAA.S6710     Document Type: Article

References (148)

1. Holgate ST, Polosa R. The mechanisms, diagnosis, and management of severe asthma in adults. Lancet. 2006;368(9537):780-793.
2. The ENFUMOSA cross-sectional European multicentre study of the clinical phenotype of chronic severe asthma. European network for understanding mechanisms of severe asthma. Eur Respir J. 2003;22(3): 470-477.
3. Van Ganse E, Laforest L, Pietri G, et al. Persistent asthma: disease control, resource utilisation and direct costs. Eur Respir J. 2002;20(2):260-267.
4. Antoncelli L, Bucca C, Neri M, De Benedetto F, Saabbatani PBF. Asthma severity and medical resource utilization. Eur Respir J. 2004; 23:723-729.
5. Godard P, Chanez P, Siraudin L, Nicoloyannis N, Duru G. Costs of asthma are correlated with severity: a 1-yr prospective study. Eur Respir J. 2002;19(1):61-67.
6. Global Initiative for Asthma. Global strategy for asthma management and prevention. A six part management program. NIH publication number 02-3659. 2006.
7. Chung KF, Godard P, Adelroth E, et al. Difficult/therapy-resistant asthma: the need for an integrated approach to def ine clinical phenotypes, evaluate risk factors, understand pathophysiology and find novel therapies. ERS Task Force on Difficult/Therapy-Resistant Asthma. European Respiratory Society. Eur Respir J. 1999;13(5):1198-1208.
8. Wenzel S, Fahy JV, Irvin CG, Peters SP, Spector S, Szefler SJ. Proceedings of the ATS Workshop on Refractory Asthma: current understanding, recommendations and unanswered questions. Am J Respir Crit Care Med. 2000;162:2341-2351.
9. Wenzel S. Severe asthma in adults. Am J Respir Crit Care Med. 2005; 172(2):149-160.
10. Polosa R, Benfatto GT. Managing patients with chronic severe asthma: rise to the challenge. Eur J Intern Med. 2009;20(2):114-124.
11. Chanez P, Wenzel S., Anderson GP, et al. Severe asthma in adults: what are the important questions? J Allergy Clin Immunol. 2007;119(6): 1337-1348.
12. GINA Report, Global Strategy for Asthma Management and Prevention. NIH publication number 02-3659. 2009.
13. Polosa R, Morjaria J. Immunomodulatory and biologic therapies for severe refractory asthma. Respir Med. 2008;102(11):1499-1510.
14. Bucknall CE, Slack R, Godley CC, Mackay TW, Wright SC. Scottish Confidential Inquiry into Asthma Deaths (SCIAD), 1994-6. Thorax. 1999;54(11):978-984.
15. Bender BG. Overcoming barriers to nonadherence in asthma treatment. J Allergy Clin Immunol. 2002;109 Suppl 6:S554-S559.
16. Weinstein AG. Should patients with persistent severe asthma be monitored for medication adherence? Ann Allergy Asthma Immunol. 2005; 94(2):251-257.
17. Currie GP, Douglas JG, Heaney LG. Difficult to treat asthma in adults. BMJ. 2009;338:b494.
18. Robinson DS, Campbell DA, Durham SR, Pfeffer J, Barnes PJ, Chung KF. Systematic assessment of difficult-to-treat asthma. Eur Respir J. 2003;22(3):478-483.
19. Cochrane GM, Horne R, Chanez P. Compliance in asthma. Respir Med. 1999;93(11):763-769.
20. Moore WC, Bleecker ER, Curran-Everett D, et al. Characterization of the severe asthma phenotype by the National Heart, Lung, and Blood Institute’s Severe Asthma Research Program. J Allergy Clin Immunol. 2007;119(2):405-413.
21. British Thoracic Society and Scottish Intercollegiate Guideline Network. British guideline on the management of asthma. Thorax. 2008; 63 Suppl 4:iv1-iv121.
22. Crapo RO, Casaburi R, Coates AL, et al. Guidelines for methacholine and exercise challenge testing-1999. This official statement of the American Thoracic Society was adopted by the ATS Board of Directors, July 1999. Am J Respir Crit Care Med. 2000;161(1):309-329.
23. Tinkelman DG, Price DB, Nordyke RJ, Halbert RJ. Misdiagnosis of COPD and asthma in primary care patients 40 years of age and over. J Asthma. 2006;43(1):75-80.
24. Greenberger PA. Allergic bronchopulmonary aspergillosis, allergic fungal sinusitis, and hypersensitivity pneumonitis. Clin Allergy Immunol. 2002;16:449-468.
25. Noth I, Strek ME, Leff AR. Churg-Strauss syndrome. Lancet. 2003; 361(9357):587-594.
26. Goldman J, Muers M. Vocal cord dysfunction and wheezing. Thorax. 1991;46(6):401-404.
27. Wood RP 2nd, Milgrom H. Vocal cord dysfunction. J Allergy Clin Immunol. 1996;98(3):481-485.
28. Heaney LG, Conway E, Kelly C, et al. Predictors of therapy resistant asthma: outcome of a systematic evaluation protocol. Thorax. 2003; 58(7):561-566.
29. ten Brinke A, Grootendorst DC, Schmidt JT, et al. Chronic sinusitis in severe asthma is related to sputum eosinophilia. J Allergy Clin Immunol. 2002;109(4):621-626.
30. Bresciani M, Paradis L, Des Roches A, et al. Rhinosinusitis in severe asthma. J Allergy Clin Immunol. 2001;107(1):73-80.
31. Mascia K, Haselkorn T, Deniz YM, Miller DP, Bleecker ER, Borish L. Aspirin sensitivity and severity of asthma: evidence for irreversible airway obstruction in patients with severe or difficult-to-treat asthma. J Allergy Clin Immunol. 2005;116(5):970-975.
32. Corren J. Allergic rhinitis and asthma: how important is the link? J Allergy Clin Immunol. 1997;99(2):S781-S786.
33. Ceylan E, Gencer M, San I. Nasal polyps and the severity of asthma. Respirology. 2007;12(2):272-276.
34. Field SK, Underwood M, Brant R, Cowie RL. Prevalence of gastroesophageal reflux symptoms in asthma. Chest. 1996;109(2):316-322.
35. Littner MR, Leung FW, Ballard ED 2nd, Huang B, Samra NK. Effects of 24 weeks of lansoprazole therapy on asthma symptoms, exacerbations, quality of life, and pulmonary function in adult asthmatic patients with acid reflux symptoms. Chest. 2005;128(3):1128-1135.
36. Kiljander TO, Harding SM, Field SK, et al. Effects of esomeprazole 40 mg twice daily on asthma: a randomized placebo-controlled trial. Am J Respir Crit Care Med. 2006;173(10):1091-1097.
37. Leggett JJ, Johnston BT, Mills M, Gamble J, Heaney LG. Prevalence of gastroesophageal reflux in difficult asthma: relationship to asthma outcome. Chest. 2005;127(4):1227-1231.
38. Mastronarde JG, Anthonisen NR, Castro M, et al. Efficacy of esomeprazole for treatment of poorly controlled asthma. N Engl J Med. 2009; 360(15):1487-1499.
39. Collins JE, Gill TK, Chittleborough CR, Martin AJ, Taylor AW, Winefield H. Mental, emotional, and social problems among school children with asthma. J Asthma. 2008;45(6):489-493.
40. Miles JF, Garden GM, Tunnicliffe WS, Cayton RM, Ayres JG. Psychological morbidity and coping skills in patients with brittle and non-brittle asthma: a case-control study. Clin Exp Allergy. 1997;27(10):1151-1159.
41. Roy-Byrne PP, Davidson KW, Kessler RC, et al. Anxiety disorders and comorbid medical illness. Gen Hosp Psychiatry. 2008;30(3):208-225.
42. Kullowatz A, Rosenfield D, Dahme B, Magnussen H, Kanniess F, Ritz T. Stress effects on lung function in asthma are mediated by changes in airway inflammation. Psychosom Med. 2008;70(4):468-475.
43. Lange P, Parner J, Vestbo J, Schnohr P, Jensen G. A 15-year follow-up study of ventilatory function in adults with asthma. N Engl J Med. 1998; 339(17):1194-1200.
44. Eisner MD, Iribarren C. The influence of cigarette smoking on adult asthma outcomes. Nicotine Tob Res. 2007;9(1):53-56.
45. Marquette CH, Saulnier F, Leroy O, et al. Long-term prognosis of nearfatal asthma. A 6-year follow-up study of 145 asthmatic patients who underwent mechanical ventilation for a near-fatal attack of asthma. Am Rev Respir Dis. 1992;146(1):76-81.
46. Chaudhuri R, Livingston E, McMahon AD, Thomson L, Borland W, Thomson NC. Cigarette smoking impairs the therapeutic response to oral corticosteroids in chronic asthma. Am J Respir Crit Care Med. 20031;168(11):1308-1311.
47. Tomlinson JE, McMahon AD, Chaudhuri R, Thompson JM, Wood SF, Thomson NC. Efficacy of low and high dose inhaled corticosteroid in smokers versus non-smokers with mild asthma. Thorax. 2005;60(4):282-287.
48. Polosa R, Knoke JD, Russo C, et al. Cigarette smoking is associated with a greater risk of incident asthma in allergic rhinitis. J Allergy Clin Immunol. 2008;121(6):1428-1434.
49. Currie GP, Jackson CM, Lee DK, Lipworth BJ. Allergen sensitization and bronchial hyper-responsiveness to adenosine monophosphate in asthmatic patients. Clin Exp Allergy. 2003;33(10):1405-1408.
50. Le Moual N, Siroux V, Pin I, Kauffmann F, Kennedy SM. Asthma severity and exposure to occupational asthmogens. Am J Respir Crit Care Med. 2005;172(4):440-445.
51. Sin DD, Sutherland ER. Obesity and the lung: 4. Obesity and asthma. Thorax. 2008;63(11):1018-1023.
52. van Veen IH, ten Brinke A, Sterk PJ, Rabe KF, Bel EH. Airway inflammation in obese and nonobese patients with difficult-to-treat asthma. Allergy. 2008;63(5):570-574.
53. Camargo CA Jr, Weiss ST, Zhang S, Willett WC, Speizer FE. Prospective study of body mass index, weight change, and risk of adult-onset asthma in women. Arch Intern Med. 1999;159(21):2582-2588.
54. Hakala K, Stenius-Aarniala B, Sovijarvi A. Effects of weight loss on peak flow variability, airways obstruction, and lung volumes in obese patients with asthma. Chest. 2000;118(5):1315-1321.
55. Stenius-Aarniala B, Poussa T, Kvarnstrom J, Gronlund EL, Ylikahri M, Mustajoki P. Immediate and long term effects of weight reduction in obese people with asthma: randomised controlled study. BMJ. 2000;320(7238):827-832.
56. http://www.fp7-consulting.be/en/ubiopred/. 2008.
57. Wenzel S., Schwartz LB, Langmack EL, et al. Evidence that severe asthma can be divided pathologically into two inflammatory subtypes with distinct physiologic and clinical characteristics. Am J Respir Crit Care Med. 1999;160(3):1001-1008.
58. Ito K, Chung KF, Adcock IM. Update on glucocorticoid action and resistance. J Allergy Clin Immunol. 2006;117(3):522-543.
59. Roberts NJ, Robinson DS, Partridge MR. How is difficult asthma managed? Eur Respir J. 2006;28(5):968-973.
60. Noonan M, Chervinsky P, Busse WW, et al. Fluticasone propionate reduces oral prednisone use while it improves asthma control and quality of life. Am J Respir Crit Care Med. 1995;152(5 Pt 1):1467-1473.
61. Gibson PG, Powell H, Ducharme F. Long-acting beta2-agonists as an inhaled corticosteroid-sparing agent for chronic asthma in adults and children. Cochrane Database Syst Rev. 2005;(4):CD005076.
62. Nightingale JA, Rogers DF, Barnes PJ. Comparison of the effects of salmeterol and formoterol in patients with severe asthma. Chest. 2002; 21(5):1401-1406.
63. Guyer B, Gibbs R, Feldsien D, Wenzel S. A pilot study to evaluate the bronchodilator response pattern to salmeterol in refractory asthma. J Allergy Clin Immunol. 2002:109(S244).
64. Tonelli M, Zingoni M, Bacci E, et al. Short-term effect of the addition of leukotriene receptor antagonists to the current therapy in severe asthmatics. Pulm Pharmacol Ther. 2003;16(4):237-240.
65. Rodrigo GJ, Rodrigo C. Triple inhaled drug protocol for the treatment of acute severe asthma. Chest. 2003;123(6):1908-1915.
66. Virchow JC, Lommatzch M editors. Anticholinergic agents in asthma. Oxford: Clinical Publishing, 2007.
67. Vatrella A, Ponticiello A, Pelaia G, Parrella R, Cazzola M. Bronchodilating effects of salmeterol, theophylline and their combination in patients with moderate to severe asthma. Pulm Pharmacol Ther. 2005;18(2):89-92.
68. Roberts G, Newsom D, Gomez K, et al. Intravenous salbutamol bolus compared with an aminophylline infusion in children with severe asthma: a randomised controlled trial. Thorax. 2003;58(4):306-310.
69. Silverman RA, Osborn H, Runge J, et al. IV magnesium sulfate in the treatment of acute severe asthma: a multicenter randomized controlled trial. Chest. 2002;122(2):489-497.
70. Beasley R, Aldington S. Magnesium in the treatment of asthma. Curr Opin Allergy Clin Immunol. 2007;7(1):107-110.
71. Mortimer KJ, Tattersfield AE. Benefit versus risk for oral, inhaled, and nasal glucocorticosteroids. Immunol Allergy Clin North Am. 2005; 25(3):523-539.
72. Keenan GF. Management of complications of glucocorticoid therapy. Clin Chest Med. 1997;18(3):507-520.
73. Joseph A, Brasington R, Kahl L, Ranganathan P, Cheng TP, Atkinson J. Immunologic rheumatic disorders. J Allergy Clin Immunol. 125(2 Suppl 2): S204-S215.
74. Comet R, Domingo C, Larrosa M, et al. Benefits of low weekly doses of methotrexate in steroid-dependent asthmatic patients. A doubleblind, randomized, placebo-controlled study. Respir Med. 2006;100(3): 411-419.
75. Hedman J, Seideman P, Albertioni F, Stenius-Aarniala B. Controlled trial of methotrexate in patients with severe chronic asthma. Eur J Clin Pharmacol. 1996;49(5):347-349.
76. Trigg CJ, Davies RJ. Comparison of methotrexate 30 mg per week with placebo in chronic steroid-dependent asthma: a 12-week double-blind, cross-over study. Respir Med. 1993;87(3):211-216.
77. Mullarkey MF, Lammert JK, Blumenstein BA. Long-term methotrexate treatment in corticosteroid-dependent asthma. Ann Intern Med. 1990; 112(8):577-581.
78. Shiner RJ, Katz I, Shulimzon T, Silkoff P, Benzaray S. Methotrexate in steroid-dependent asthma: long-term results. Allergy. 1994;49(7): 565-568.
79. Domingo C, Moreno A, Amengual MJ, Comet R, Lujan M. Twelve years’ experience with methotrexate for GINA treatment step 5 asthma patients. Curr Med Res Opin. 2009;25(2):367-374.
80. Aaron SD, Dales RE, Pham B. Management of steroid-dependent asthma with methotrexate: a meta-analysis of randomized clinical trials. Respir Med. 1998;92(8):1059-1065.
81. Davies H, Olson L, Gibson P. Methotrexate as a steroid sparing agent for asthma in adults. Cochrane Database Syst Rev. 2000(2):CD000391.
82. Marin MG. Low-dose methotrexate spares steroid usage in steroid-dependent asthmatic patients: a meta-analysis. Chest. 1997;112(1):29-33.
83. Corrigan CJ, Kay AB. T cells and eosinophils in the pathogenesis of asthma. Immunol Today. 1992;13(12):501-507.
84. Fukuda T, Asakawa J, Motojima S, Makino S. Cyclosporine A reduces T lymphocyte activity and improves airway hyperresponsiveness in corticosteroid-dependent chronic severe asthma. Ann Allergy Asthma Immunol. 1995;75(1):65-72.
85. Khan LN, Kon OM, Macfarlane AJ, et al. Attenuation of the allergeninduced late asthmatic reaction by cyclosporin A is associated with inhibition of bronchial eosinophils, interleukin-5, granulocyte macrophage colony-stimulating factor, and eotaxin. Am J Respir Crit Care Med. 2000;162(4 Pt 1):1377-1382.
86. Sihra BS, Kon OM, Durham SR, Walker S, Barnes NC, Kay AB. Effect of cyclosporin A on the allergen-induced late asthmatic reaction. Thorax. 1997;52(5):447-452.
87. Lock SH, Kay AB, Barnes NC. Double-blind, placebo-controlled study of cyclosporin A as a corticosteroid-sparing agent in corticosteroid-dependent asthma. Am J Respir Crit Care Med. 1996;153(2):509-514.
88. Nizankowska E, Soja J, Pinis G, et al. Treatment of steroid-dependent bronchial asthma with cyclosporin. Eur Respir J. 1995;8(7):1091-1099.
89. Alexander AG, Barnes NC, Kay AB. Trial of cyclosporin in corticosteroid-dependent chronic severe asthma. Lancet. 1992;39(8789): 324-328.
90. Nizankowska E, Dworski R, Szczeklik A. Cyclosporin for a severe case of aspirin-induced asthma. Eur Respir J. 1991;4(3):380.
91. Szczeklik A, Nizankowska E, Dworski R, Domagala B, Pinis G. Cyclosporin for steroid-dependent asthma. Allergy. 1991;46(4):312-315.
92. Evans DJ, Cullinan P, Geddes DM. Cyclosporin as an oral corticosteroid sparing agent in stable asthma. Cochrane Database Syst Rev. 2001;(2):CD002993.
93. Dougados M, Awada H, Amor B. Cyclosporin in rheumatoid arthritis: a double blind, placebo controlled study in 52 patients. Ann Rheum Dis. 1988;47(2):127-133.
94. Kornbluth A, Present DH, Lichtiger S, Hanauer S. Cyclosporin for severe ulcerative colitis: a user’s guide. Am J Gastroenterol. 1997;92(9): 1424-1428.
95. Spector SL, Katz FH, Farr RS. Troleandromycin: effectiveness in steroid-dependent asthma and bronchitis. J Allergy Clin Immunol. 1974;54(6):367-379.
96. Szefler SJ, Rose JQ, Ellis EF, Spector SL, Green AW, Jusko WJ. The effect of troleandomycin on methylprednisolone elimination. J Allergy Clin Immunol. 1980;66(6):447-451.
97. Black PN, Blasi F, Jenkins CR, et al. Trial of roxithromycin in subjects with asthma and serological evidence of infection with Chlamydia pneumoniae. Am J Respir Crit Care Med. 2001;164(4):536-541.
98. Johnston SL, Blasi F, Black PN, Martin RJ, Farrell DJ, Nieman RB. The effect of telithromycin in acute exacerbations of asthma. N Engl J Med. 2006;354(15):1589-1600.
99. Ball BD, Hill MR, Brenner M, Sanks R, Szefler SJ. Effect of lowdose troleandomycin on glucocorticoid pharmacokinetics and airway hyperresponsiveness in severely asthmatic children. Ann Allergy. 1990; 65(1):37-45.
100. Kamada AK, Hill MR, Ikle DN, Brenner AM, Szefler SJ. Efficacy and safety of low-dose troleandomycin therapy in children with severe, steroid-requiring asthma. J Allergy Clin Immunol. 1993;91(4):873-882.
101. Nelson HS, Hamilos DL, Corsello PR, Levesque NV, Buchmeier AD, Bucher BL. A double-blind study of troleandomycin and methylprednisolone in asthmatic subjects who require daily corticosteroids. Am Rev Respir Dis. 1993;147(2):398-404.
102. Garey KW, Rubinstein I, Gotfried MH, Khan IJ, Varma S, Danziger LH. Long-term clarithromycin decreases prednisone requirements in elderly patients with prednisone-dependent asthma. Chest. 2000;118(6):1826-1827.
103. Gotfried MH, Jung R, Messick C, et al. Effects of Six-Week Clarithromycin Therapy in Corticosteroid-Dependent Asthma: A Randomized Double-Blind, Placebo-Controlled Pilot Study. Curr Ther Res Clin Exp. 2004;65(1):1-12.
104. Simpson JL, Powell H, Boyle MJ, Scott RJ, Gibson PG. Clarithromycin targets neutrophilic airway inflammation in refractory asthma. Am J Respir Crit Care Med. 2008;177(2):148-155.
105. Omalizumab for persistent allergic asthma. In: Excellence NIoC, editor. London: NICE technology appraisal guidance; 2007:133.
106. Gould HJ, Sutton BJ. IgE in allergy and asthma today. Nat Rev Immunol. 2008;8(3):205-217.
107. Presta L, Shields R, O’Connell L, et al. The binding site on human immunoglobulin E for its high affinity receptor. J Biol Chem. 1994; 269(42):26368-26373.
108. Shields RL, Whether WR, Zioncheck K, et al. Inhibition of allergic reactions with antibodies to IgE. Int Arch Allergy Immunol. 1995; 107(1-3):308-312.
109. Boulet LP, Chapman KR, Cote J, et al. Inhibitory effects of an anti-IgE antibody E25 on allergen-induced early asthmatic response. Am J Respir Crit Care Med. 1997;155(6):1835-1840.
110. Fahy JV, Fleming HE, Wong HH, et al. The effect of an anti-IgE monoclonal antibody on the early-and late-phase responses to allergen inhalation in asthmatic subjects. Am J Respir Crit Care Med. 1997; 155(6):1828-1834.
111. Walker S, Monteil M, Phelan K, Lasserson TJ, Walters EH. Anti-IgE for chronic asthma in adults and children. Cochrane Database Syst Rev. 2006(2):CD003559.
112. Bousquet J, Cabrera P, Berkman N, et al. The effect of treatment with omalizumab, an anti-IgE antibody, on asthma exacerbations and emergency medical visits in patients with severe persistent asthma. Allergy. 2005;60(3):302-308.
113. Bousquet J, Wenzel S, Holgate S, Lumry W, Freeman P, Fox H. Predicting response to omalizumab, an anti-IgE antibody, in patients with allergic asthma. Chest. 2004;125(4):1378-1386.
114. Chipps B, Corren J, Finn A, Hedgecock S, Fox H, Blogg M. Omalizumab significantly improves quality of life in patients with severe persistent asthma. J Allergy Clin Immunol. 2005;115(2):S5-S19.
115. Finn A, Gross G, van Bavel J, et al. Omalizumab improves asthmarelated quality of life in patients with severe allergic asthma. J Allergy Clin Immunol. 2003;111(2):278-284.
116. Vignola AM, Humbert M, Bousquet J, et al. Efficacy and tolerability of anti-immunoglobulin E therapy with omalizumab in patients with concomitant allergic asthma and persistent allergic rhinitis: SOLAR. Allergy. 2004;59(7):709-717.
117. Cruz AA, Lima F, Sarinho E, et al. Safety of anti-immunoglobulin E therapy with omalizumab in allergic patients at risk of geohelminth infection. Clin Exp Allergy. 2007;37(2):197-207.
118. Cazzola M, Polosa R. Anti-TNF-alpha and Th1 cytokine-directed therapies for the treatment of asthma. Curr Opin Allergy Clin Immunol. 2006;6(1):43-50.
119. Morjaria J., Babu KS, Holgate ST, Polosa R. Tumour necrosis factor alpha as a therapeutic target in asthma. Drug Discov Today Ther Strateg. 2006;3(3):309-316.
120. Feldmann M, Maini R; for Lasker Clinical Medical Research Award. TNF defined as a therapeutic target for rheumatoid arthritis and other autoimmune diseases. Nat Med. 2003;9:1245-1250.
121. Erin EM, Leaker BR, Nicholson GC, et al. The effects of a monoclonal antibody directed against tumour necrosis factor-{alpha} (TNF-{alpha}) in asthma. Am J Respir Crit Care Med. 2006.
122. Rouhani FN, Meitin CA, Kaler M, Miskinis-Hilligoss D, Stylianou M, Levine SJ. Effect of tumor necrosis factor antagonism on allergenmediated asthmatic airway inflammation. Respir Med. 2005;99(9): 1175-1182.
123. Berry MA, Hargadon B, Shelley M, et al. Evidence of a role of tumor necrosis factor alpha in refractory asthma. N Engl J Med. 2006; 354(7):697-708.
124. Howarth PH, Babu KS, Arshad HS, et al. Tumour Necrosis Factor (TNF {alpha}) as a novel therapeutic target in symptomatic corticosteroid-dependent asthma. Thorax. 2005.
125. Morjaria J., Chauhan AJ, Babu KS, Polosa R, Davies DE, Holgate ST. The role of a soluble TNF-A receptor fusion protein (Etanercept) in corticosteroid-refractory asthma: a double blind, randomised placebocontrolled trial. Thorax. 2008.
126. Wenzel S., Barnes PJ, Bleecker ER, et al. A randomized, doubleblind, placebo-controlled study of tumor necrosis factor-alpha blockade in severe persistent asthma. Am J Respir Crit Care Med. 2009; 179(7):549-558.
127. Bongartz T, Sutton AJ, Sweeting MJ, Buchan I, Matteson EL, Montori V. Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials. JAMA. 2006;295(19):2275-2285.
128. Desai D, Brightling C. Cytokine and anti-cytokine therapy in asthma: ready for the clinic? Clin Exp Immunol. 2009;158(1):10-19.
129. Leckie MJ, ten Brinke A, Khan J, et al. Effects of an interleukin-5 blocking monoclonal antibody on eosinophils, airway hyper-responsiveness, and the late asthmatic response. Lancet. 2000;356(9248): 2144-2148.
130. Flood-Page PT, Menzies-Gow AN, Kay AB, Robinson DS. Eosinophil’s role remains uncertain as anti-interleukin-5 only partially depletes numbers in asthmatic airway. Am J Respir Crit Care Med. 2003;167(2): 199-204.
131. Flood-Page P, Swenson C, Faiferman I, et al. A study to evaluate safety and efficacy of mepolizumab in patients with moderate persistent asthma. Am J Respir Crit Care Med. 2007;176(11):1062-1071.
132. Kips JC, O’Connor BJ, Langley SJ, et al. Effect of SCH55700, a humanized anti-human interleukin-5 antibody, in severe persistent asthma: a pilot study. Am J Respir Crit Care Med. 2003;167(12): 1655-1659.
133. Flood-Page P, Menzies-Gow A, Phipps S, et al. Anti-IL-5 treatment reduces deposition of ECM proteins in the bronchial subepithelial basement membrane of mild atopic asthmatics. J Clin Invest. 2003;112(7):1029-1036.
134. Haldar P, Brightling C., Hargadon B, et al. Mepolizumab and exacerbations of refractory eosinophilic asthma. N Engl J Med. 2009; 360(10):973-984.
135. Nair P, Pizzichini MM, Kjarsgaard M, et al. Mepolizumab for prednisone-dependent asthma with sputum eosinophilia. N Engl J Med. 2009;360(10):985-993.
136. Azzawi M, Johnston PW, Majumdar S, Kay AB, Jeffery PK. T lymphocytes and activated eosinophils in airway mucosa in fatal asthma and cystic fibrosis. Am Rev Respir Dis. 1992;145(6):1477-1482.
137. Park CS, Lee SM, Chung SW, Uh S, Kim HT, Kim YH. Interleukin-2 and soluble interleukin-2 receptor in bronchoalveolar lavage fluid from patients with bronchial asthma. Chest. 1994;106(2):400-406.
138. Kon OM, Kay AB. Anti-T cell strategies in asthma. Inflamm Res. 1999;48(10):516-523.
139. Robinson DS, Bentley AM, Hartnell A, Kay AB, Durham SR. Activated memory T helper cells in bronchoalveolar lavage fluid from patients with atopic asthma: relation to asthma symptoms, lung function, and bronchial responsiveness. Thorax. 1993;48(1):26-32.
140. Busse WW, Israel E, Nelson HS, et al. Daclizumab improves asthma control in patients with moderate to severe persistent asthma: a randomized, controlled trial. Am J Respir Crit Care Med. 2008;178(10):1002-1008.
141. Woodruff PG, Dolganov GM, Ferrando RE, et al. Hyperplasia of smooth muscle in mild to moderate asthma without changes in cell size or gene expression. Am J Respir Crit Care Med. 2004;169(9):1001-1006.
142. Carroll N, Elliot J, Morton A, James A. The structure of large and small airways in nonfatal and fatal asthma. Am Rev Respir Dis. 1993;147(2):405-410.
143. Danek CJ, Lombard CM, Dungworth DL, et al. Reduction in airway hyperresponsiveness to methacholine by the application of RF energy in dogs. J Appl Physiol. 2004;97(5):1946-1953.
144. Miller JD, Cox G, Vincic L, Lombard CM, Loomas BE, Danek CJ. A prospective feasibility study of bronchial thermoplasty in the human airway. Chest. 2005;127(6):1999-2006.
145. Cox G, Miller JD, McWilliams A, Fitzgerald JM, Lam S. Bronchial thermoplasty for asthma. Am J Respir Crit Care Med. 2006;173(9): 965-969.
146. Cox G, Thomson NC, Rubin AS, et al. Asthma control during the year after bronchial thermoplasty. N Engl J Med. 2007;356(13): 1327-1337.
147. Pavord ID, Cox G, Thomson NC, et al. Safety and efficacy of bronchial thermoplasty in symptomatic, severe asthma. Am J Respir Crit Care Med. 2007;176(12):1185-1191.
148. Castro M, Rubin AS, Laviolette M, et al. Effectiveness and safety of bronchial thermoplasty in the treatment of severe asthma: a multicenter, randomized, double-blind, sham-controlled clinical trial. Am J Respir Crit Care Med. 181(2):116-124.